# Therapeutic Human Polyclonals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/therapeutic-human-polyclonals

- Industry: Biotechnology
- Headquarters: Mountain View, US
- Website: www.polyclonals.com
- Total disclosed funding: $5M
- Latest round: Series B (Nov 1, 2002)
- Investors on record: 2

## About

Therapeutic Human Polyclonals Inc. specializes in the development and sale of domain names, serving as a key intermediary for clients seeking to enhance their online presence through unique digital properties.Therapeutic Human Polyclonals Inc. operates as a domain name brokerage, offering crucial digital branding services. The firm is headquartered in Mountain View, US. In March 2007, the company was acquired by Roche for USD 56.50 million, marking a pivotal moment in its corporate journey. The founder has a background in establishing similar ventures in the past, contributing to the company’s domain expertise and market understanding.PolyClonals.com primarily offers domain names for sale, serving as an intermediary for clients seeking to acquire digital properties. The company's core product is the sale of domain names, which are essential for establishing an online presence, whether for personal branding, e-commerce, or corporate identity. By enabling users to purchase domain names such as PolyClonals.com, which is offered at USD 1,795 or through flexible payment plans, the company addresses the need for unique web addresses that enhance visibility and accessibility in the digital domain. The platform caters to a diverse clientele, including entrepreneurs, small business owners, and established corporations, aiming to simplify the domain acquisition process while ensuring customer satisfaction. PolyClonals.com primarily targets markets in North America and Europe, facilitating transactions across various sectors that require domain registration.The revenue model of PolyClonals.com revolves around direct sales of domain names, with options for immediate purchase or installment payment plans. By offering a price point of USD 1,795 or monthly payments of USD 74.79 over 24 months, the company attracts a wide customer base looking for manageable financing options. The transaction structure is predominantly B2C, where individual customers or businesses purchase domain names through the website. The company emphasizes ease of access and quick delivery, typically providing domain access within one to two hours of purchase. With a commitment to customer satisfaction, PolyClonals.com offers a 30-day money-back guarantee, ensuring a seamless purchasing experience that fosters confidence and loyalty among its clients.Following its acquisition by Roche, Therapeutic Human Polyclonals Inc. plans to leverage this partnership to enhance its offerings in the domain name market. Although no new products are currently announced, the company anticipates expanding its reach into new markets in Asia and South America by 2008. The funding from the recent acquisition will support these initiatives by bolstering marketing efforts and enhancing the technological framework necessary for seamless transactions.

## Funding rounds

- Series B, Nov 1, 2002, $5M — Research Corporation Technologies, SangStat Medical Corporation
- Series A, Jun 1, 2000 — Research Corporation Technologies

## Investors

- Research Corporation Technologies (https://capitalatlas.ai/funds/research-corporation-technologies) — Series A, Series B
- SangStat Medical Corporation — Series B